Newham Centre for Mental Health, Unit for Social and Community Psychiatry, Queen Mary University of London, London, United Kingdom.
Research & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, United Kingdom.
PLoS One. 2019 Jun 20;14(6):e0218711. doi: 10.1371/journal.pone.0218711. eCollection 2019.
The widely established treatment for psychosis is long-term antipsychotic medication. However, many people stop taking this treatment, and request other options. There are also growing concerns about adverse effects, but currently no professional guidelines to support reducing or stopping these drugs. The views and experiences of individual mental health professionals around reducing and stopping antipsychotics are therefore crucial in treatment decisions.
We conducted 7 focus groups with prescribing psychiatrists and other members of community-based statutory mental health services in London. Participants discussed their views about, experiences, and processes of antipsychotic reduction and discontinuation. Data were analysed using thematic analysis.
Participants acknowledged that antipsychotics can have severe adverse effects. They were generally supportive of trying to reduce these drugs to the lowest effective dose, although stopping antipsychotics was less acceptable. Prior experiences of adverse events after reduction or discontinuation meant that both were approached with caution. Reduction was also reported to be hampered by organisational and knowledge barriers. Lack of resources, pressure to discharge, and poor continuity of care were seen as organisational barriers. Knowledge barriers included inadequate evidence about who might be best suited to reduction, and lack of guidance about how this could be done safely. This meant that reduction was often prompted by patients, and sometimes actively discouraged, and stability with maintenance treatment was often favoured.
Concerns about risk and other barriers means that clinicians are often reluctant to implement reduction or discontinuation of antipsychotic medication. In order to increase the treatment options available to service users, more research and guidance on how to minimise the risks of antipsychotic reduction and discontinuation is required to enable clinicians to engage more constructively with service users requests, offering people more choice and control in managing their mental health condition.
精神疾病的广泛治疗方法是长期使用抗精神病药物。然而,许多人停止服用这种治疗方法,并要求其他选择。人们也越来越担心副作用,但目前没有专业指南来支持减少或停止使用这些药物。因此,个别精神卫生专业人员在减少和停止使用抗精神病药物方面的观点和经验对于治疗决策至关重要。
我们在伦敦的社区法定精神卫生服务机构中进行了 7 次焦点小组讨论,参与者讨论了他们对减少和停止使用抗精神病药物的看法、经验和过程。使用主题分析对数据进行分析。
参与者承认抗精神病药物可能会产生严重的副作用。他们普遍支持尝试将这些药物减少到最低有效剂量,但停止使用抗精神病药物的接受程度较低。减少或停止使用后发生不良反应的既往经历意味着两者都需要谨慎处理。减少也因组织和知识障碍而受阻。缺乏资源、出院压力和护理连续性差被视为组织障碍。知识障碍包括谁最适合减少的证据不足,以及缺乏关于如何安全进行减少的指导。这意味着减少通常是由患者引起的,有时甚至受到积极劝阻,并且维持治疗的稳定性通常更受青睐。
对风险和其他障碍的担忧意味着临床医生通常不愿意实施减少或停止使用抗精神病药物。为了增加服务使用者可用的治疗选择,需要更多关于如何最小化减少和停止使用抗精神病药物的风险的研究和指导,以使临床医生能够更建设性地与服务使用者的需求互动,为人们提供更多的选择和控制来管理他们的心理健康状况。